Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Operating Costs and Expenses:
General and administrative	$ 1,431	$ 1,644	$ 3,051	$ 3,734
Research and development	3,572	4,831	6,942	10,891
Total Operating Costs and Expenses	5,003	6,475	9,993	14,625
Loss from Operations	(5,003)	(6,475)	(9,993)	(14,625)
Other Income:
Change in fair value of warrant liability	783	2,159	3,438	7,249
Interest income	6	1	15	3
Total Other Income	789	2,160	3,453	7,252
Net Loss	(4,214)	(4,315)	(6,540)	(7,373)
Net Loss Attributable to Non-controlling Interest	(17)	(60)	(26)	(272)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	(4,197)	(4,255)	(6,514)	(7,101)
Series A Preferred Stock Dividends	(61)		(120)	0
Net Loss Attributable to Common Stock Holders	$ (4,258)	$ (4,255)	$ (6,634)	$ (7,101)
Net Loss Per Share - Basic and Dilutive	$ (0.03)	$ (0.03)	$ (0.05)	$ (0.06)
Weighted average number of shares outstanding during the period - Basic and Dilutive	128,918,408	123,005,220	128,743,616	120,241,593